Positron Emission Tomography (PET) Imaging of Multiple Myeloma in a Post-Treatment Setting.
magnetic resonance imaging
multiple myeloma
positron emission tomography
response assessment
Journal
Diagnostics (Basel, Switzerland)
ISSN: 2075-4418
Titre abrégé: Diagnostics (Basel)
Pays: Switzerland
ID NLM: 101658402
Informations de publication
Date de publication:
03 Feb 2021
03 Feb 2021
Historique:
received:
13
12
2020
revised:
23
01
2021
accepted:
29
01
2021
entrez:
6
2
2021
pubmed:
7
2
2021
medline:
7
2
2021
Statut:
epublish
Résumé
2-deoxy-2-[18F]fluoro-D-glucose (FDG) positron emission tomography/computed tomography (FDG PET/CT) has an established clinical value in the diagnosis and initial staging of multiple myeloma (MM). In the last ten years, a vast body of literature has shown that this tool can also be of high relevance for monitoring therapy responses, making it the recommended imaging approach in this field. Starting from the strengths and weaknesses of radiological imaging in MM, the present review aims to analyze FDG PET/CT's current clinical value focusing on therapy response assessment and objective interpretation criteria for therapy monitoring. Given the potential occurrence of patients with MM showing non-FDG-avid bone disease, new opportunities can be provided by non-FDG PET tracers. Accordingly, the potential role of non-FDG PET tracers in this setting has also been discussed.
Identifiants
pubmed: 33546455
pii: diagnostics11020230
doi: 10.3390/diagnostics11020230
pmc: PMC7913723
pii:
doi:
Types de publication
Journal Article
Review
Langues
eng
Références
Blood. 2013 Mar 7;121(10):1819-23
pubmed: 23305732
Br J Haematol. 2007 Jul;138(2):176-85
pubmed: 17593024
Blood. 2017 Jul 6;130(1):30-34
pubmed: 28432222
Clin Cancer Res. 2015 Oct 1;21(19):4384-90
pubmed: 26078390
Skeletal Radiol. 2011 Jul;40(7):843-7
pubmed: 21229354
Eur J Nucl Med Mol Imaging. 2014 Jan;41(1):41-9
pubmed: 24129710
Theranostics. 2017 Jul 23;7(11):2956-2964
pubmed: 28824728
Am J Hematol. 2020 Aug;95(8):966-977
pubmed: 32350883
N Engl J Med. 2007 Jun 21;356(25):2582-90
pubmed: 17582068
Oncotarget. 2015 Apr 10;6(10):8418-29
pubmed: 25762625
Curr Probl Diagn Radiol. 2015 Sep-Oct;44(5):407-24
pubmed: 25890454
Jpn J Radiol. 2018 Jun;36(6):382-393
pubmed: 29671193
Oncotarget. 2017 Apr 11;8(15):25637-25649
pubmed: 27556189
J Clin Oncol. 2017 Sep 1;35(25):2911-2918
pubmed: 28686535
Lancet Oncol. 2019 Jun;20(6):e302-e312
pubmed: 31162104
Am J Nucl Med Mol Imaging. 2020 Oct 15;10(5):257-264
pubmed: 33224622
Clin Cancer Res. 2015 Jan 1;21(1):106-12
pubmed: 25351744
Int J Radiat Oncol Biol Phys. 2009 Jul 1;74(3):740-6
pubmed: 19038505
Radiology. 2014 Jun;271(3):785-94
pubmed: 24475858
Skeletal Radiol. 2002 Dec;31(12):690-4
pubmed: 12483429
Eur Radiol. 2020 Sep 23;:
pubmed: 32965573
Eur J Nucl Med Mol Imaging. 2018 Sep;45(10):1694-1704
pubmed: 29610955
Eur J Radiol. 2020 Dec;133:109403
pubmed: 33202373
Acad Radiol. 2018 Jul;25(7):904-914
pubmed: 29373210
Clin Nucl Med. 2017 Feb;42(2):e130-e134
pubmed: 27922862
AJR Am J Roentgenol. 2005 Apr;184(4):1199-204
pubmed: 15788594
Front Med (Lausanne). 2019 Apr 09;6:69
pubmed: 31024917
Eur J Haematol. 2014 Nov;93(5):407-13
pubmed: 24809596
Eur J Haematol. 2011 Apr;86(4):289-98
pubmed: 21198866
Eur J Haematol. 2004 Jan;72(1):32-7
pubmed: 14962260
Eur J Nucl Med Mol Imaging. 2019 Jun;46(6):1345-1350
pubmed: 30903198
J Clin Oncol. 2015 Feb 20;33(6):657-64
pubmed: 25605835
Blood. 2009 Sep 3;114(10):2068-76
pubmed: 19443657
EJNMMI Res. 2018 Apr 10;8(1):28
pubmed: 29633046
J Nucl Med. 2002 Nov;43(11):1457-63
pubmed: 12411548
Br J Radiol. 2012 Dec;85(1020):e1198-203
pubmed: 23175485
Radiology. 2019 Apr;291(1):5-13
pubmed: 30806604
Contrast Media Mol Imaging. 2018 Jul 30;2018:4198673
pubmed: 30154686
Eur J Nucl Med Mol Imaging. 2016 Mar;43(3):414-21
pubmed: 26475305
Clin Nucl Med. 2019 Aug;44(8):620-624
pubmed: 31274607
Nat Rev Clin Oncol. 2018 Jul;15(7):409-421
pubmed: 29686421
Eur J Nucl Med Mol Imaging. 2012 Mar;39(3):493-500
pubmed: 22113619
Eur Radiol. 2013 Feb;23(2):570-8
pubmed: 22843058
Clin Nucl Med. 2017 Feb;42(2):e126-e127
pubmed: 27941377
Biol Blood Marrow Transplant. 2015 Jun;21(6):1068-73
pubmed: 25754658
Lancet Oncol. 2017 Apr;18(4):e206-e217
pubmed: 28368259
Eur J Nucl Med Mol Imaging. 2017 Jan;44(1):50-62
pubmed: 27573638
Clin Nucl Med. 2017 Nov;42(11):e469-e471
pubmed: 28872550
J Nucl Med. 2013 May;54(5):683-90
pubmed: 23516309
Theranostics. 2017 Jan 1;7(1):205-212
pubmed: 28042328
Clin Nucl Med. 2013 Feb;38(2):e74-9
pubmed: 23143049
Clin Cancer Res. 2017 Apr 15;23(8):1981-1987
pubmed: 27698001
Oncotarget. 2014 Sep 15;5(17):7381-91
pubmed: 25277179
Anticancer Res. 2019 Apr;39(4):1943-1952
pubmed: 30952737
Eur J Nucl Med Mol Imaging. 2019 Jan;46(1):116-128
pubmed: 30054697
Eur J Radiol. 2016 Feb;85(2):373-82
pubmed: 26781143
Eur J Radiol. 2012 Dec;81(12):4013-8
pubmed: 22921683
Eur J Nucl Med Mol Imaging. 2018 May;45(5):712-719
pubmed: 29270787
Eur J Radiol. 2014 Dec;83(12):2203-2223
pubmed: 25308249
Haematologica. 2007 Jan;92(1):50-5
pubmed: 17229635
Cancers (Basel). 2020 Apr 23;12(4):
pubmed: 32340251
PLoS One. 2017 May 4;12(5):e0177125
pubmed: 28472196
Clin Cancer Res. 2018 Nov 1;24(21):5219-5224
pubmed: 30068709
Clin Nucl Med. 2009 Sep;34(9):576-84
pubmed: 19692817
EJNMMI Res. 2015 Apr 29;5:28
pubmed: 25984435
Oncotarget. 2018 Jan 3;9(10):9061-9072
pubmed: 29507674
Biol Blood Marrow Transplant. 2018 Feb;24(2):406-409
pubmed: 29032267
J Nucl Med. 2012 Dec;53(12):1829-35
pubmed: 23071351
Br J Haematol. 2015 Oct;171(1):29-37
pubmed: 26013304
Eur J Nucl Med Mol Imaging. 2015 Feb;42(2):328-54
pubmed: 25452219
Blood. 2011 Dec 1;118(23):5989-95
pubmed: 21900189
J Clin Oncol. 2021 Jan 10;39(2):116-125
pubmed: 33151787